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mepolizumab-treated versus 19% of placebo-treated patients
with eosinophilic granulomatosis with polyangiitis (EGPA)
achieved protocol-defined remission.
Objective: We sought to investigate post hoc the clinical benefit
of mepolizumab in patients with EGPA using a comprehensive
definition of benefit encompassing remission, oral glucocorticoid
(OGC) dose reduction, and EGPA relapses.
Methods: The randomized, placebo-controlled, double-blind,
parallel-group trial recruited patients with relapsing/refractory
EGPA receiving stable OGCs (prednisolone/prednisone, >_7.5–
50 mg/d) for 4 or more weeks. Patients received 300 mg of
subcutaneous mepolizumab or placebo every 4 weeks for
52 weeks. Clinical benefit was defined post hoc as follows:
remission at any time (2 definitions used), 50% or greater OGC
dose reduction during weeks 48 to 52, or no EGPA relapses. The
2 remission definitions were Birmingham Vasculitis Activity
Score of 0 plus OGC dose of 4 mg/d or less (remission 1/clinical
benefit 1) or 7.5 mg/d or less (remission 2/clinical benefit 2).
Clinical benefit was assessed in all patients and among
subgroups with a baseline blood eosinophil count of less than
150 cells/mL, baseline OGC dosage of greater than 20 mg/d, or
weight of greater than 85 kg.
Results: With mepolizumab versus placebo, 78% versus 32% of
patients experienced clinical benefit 1, and 87% versus 53% of
patients experienced clinical benefit 2 (both P < .001).
Significantly more patients experienced clinical benefit 1 with
mepolizumab versus placebo in the blood eosinophil count less
than 150 cells/mL subgroup (72% vs 43%, P 5 .033) and weight
greater than 85 kg subgroup (68% vs 23%, P 5 .005); in the
OGC greater than 20 mg/d subgroup, results were not
significant but favored mepolizumab (60% vs 36%, P 5 .395).
Conclusion: When a comprehensive definition of clinical benefit
was applied to data from a randomized controlled trial, 78% to
87% of patients with EGPA experienced benefit with
mepolizumab. (J Allergy Clin Immunol 2019;143:2170-7.)
Key words: Eosinophilic granulomatosis with polyangiitis, Churg-
Strauss syndrome, mepolizumab, eosinophils, IL-5, vasculitis
Eosinophilic granulomatosis with polyangiitis (EGPA), previ-
ously known as Churg-Strauss syndrome, is a rare multisystem
disease characterized by asthma, sinusitis, blood and tissue
eosinophilia, and systemic necrotizing vasculitis.1,2 The precise
role of eosinophils in the pathology of EGPA remains unclear;
however, evidence of blood eosinophilia; eosinophilic tissue infil-
tration of the lungs, heart, and gastrointestinal tract; and vascular
and extravascular eosinophilic granulomatous inflammation, sug-
gests that eosinophils are central to EGPA pathogenesis.1-5
Glucocorticoids reduce blood and tissue eosinophil counts by
inducing apoptosis and inhibiting prosurvival signaling path-
ways.6 Based on long-term studies showing increased patient sur-
vival, oral glucocorticoids (OGCs) are currently recommended as
first-line treatment for EGPA.7 However, relapses occur
frequently, and many patients do not taper their OGC dose or dis-
continue OGC treatment.6,8,9 Chronic and high-dose OGC use is
associated with serious and sometimes irreversible adverse ef-
fects, including increased risk of infection, osteoporosis, and sec-
ondary adrenal insufficiency.10,11 Even short courses of high-dose
OGCs are associated with side effects.12 Immunosuppressivetherapy is also recommended for remission-induction and as
maintenance therapy in patients with EGPA.7 Although OGCs
and immunosuppressive therapies are commonly used,13 they
have not been systematically investigated in controlled trials for
EGPA. Furthermore, expert opinion and small studies suggest
that use of immunosuppressive agents does not substantially
affect relapse rates.14 Considering the inadequate efficacy of
OGCs in inducing relapse-free remission and the significant
side effect burden associated with both OGCs and other immuno-
suppressive drugs, there is a pressing need for more effective and
tolerable treatment options for EGPA.
Mepolizumab, an anti–IL-5 mAb that reduces blood and
airway eosinophil counts,3,5 has been investigated as a potential
therapy for patients with EGPA.15-17 A phase III trial was recently
conducted to assess the efficacy and safety of mepolizumab in pa-
tients with relapsing and refractory EGPA over 52 weeks.5 The
trial assessed 2 primary end points: total accrued weeks of remis-
sion (defined as BirminghamVasculitis Activity Score [BVAS] of
0 and OGC dose of <_4 mg/d) and the proportion of patients who
achieved remission at weeks 36 and 48. Overall, 28% of patients
receiving mepolizumab versus 3% of patients receiving placebo
experienced 24 or more weeks of accrued remission; 32% versus
3%, respectively, had remission at both weeks 36 and 48.
Although both primary end points were met, many patients in
the mepolizumab treatment group did not achieve protocol-
defined remission. However, it is further hypothesized that treat-
ment with mepolizumab provided clinical benefits that were not
encompassed by the trial’s predefined remission end points.
There are several aspects of clinical benefit aside from
protocol-defined remission that are important to consider when
assessing the efficacy of therapy in patients with EGPA. As such,
determining the effect of mepolizumab treatment on clinical
parameters additional to the primary and secondary end points of
the phase III trial is of relevance to clinicians and patients with
EGPA. The objective of this post hoc assessment was to gain a
broader overview of the efficacy of mepolizumab in EGPA by
investigating whether further clinical benefits in addition to those
demonstrated in the original analysis were present. To do this, pa-
tient response was assessed by using a composite definition of
clinical benefit that was based on the 3 objectives of treatment:
remission, OGC dose reduction, and a reduction in the rate of
relapse.METHODS
Study design and treatments
The study design and treatment schedule of the phase III trial (GSK ID
11592118 and NCT02020889) have been reported previously.5 In brief, the
study was a randomized, placebo-controlled, double-blind, parallel-group
multicenter trial. After screening, which occurred 1 to 4 weeks before base-
line, patients were randomly assigned (1:1) to receive 300mg of subcutaneous
mepolizumab (GlaxoSmithKline, Philadelphia, Pa) or placebo in addition to
TABLE I. Summary of patients’ demographic characteristics
and diagnostic and baseline characteristics of EGPA (as-
treated population)
_
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followed by an 8-week follow-up period. Patients’ OGC doses had to remain
stable from the initiation of screening (week -4) to week 4 but thereafter could
be reduced by the investigator with a recommended tapering schedule.Characteristic
All patients
(n 5 136)
BEC <150
cells/mL
(n 5 57)
BEC >150
cells/mL
(n 5 79)
Age (y), mean (SD) 48.5 (13.3) 50.4 (12.8) 47.1 (13.6)
Male sex, no. (%) 56 (41) 28 (49) 28 (35)
ANCA-positive status, no.
(%)*
13 (10) 5 (9) 8 (10)
BVAS >0, no. (%) 85 (63) 35 (61) 50 (63)
Immunosuppressive therapy
at baseline, no. (%)
72 (53) 34 (60) 38 (48)
Presence of EGPA diagnostic
disease characteristics at
any time during disease
course, no. (%)Patients
To be enrolled in the study, patients had to be 18 years of age or older, have
received a diagnosis of relapsing or refractory EGPA at least 6 months
previously, and have received a stable dose of OGCs (prednisolone or
prednisone, >_7.5–<_50 mg/d) with or without additional immunosuppressive
therapy for 4 or more weeks before enrollment in the study. Further details of
participant selection criteria are detailed in the primary publication.5
The trial was conducted in accordancewith the Declaration of Helsinki, the
International Conference on Harmonization Good Clinical Practice guide-
lines, and any applicable country-specific requirements. All participants
provided written informed consent. The original study was approved by each
local institutional review board.
Asthma with eosinophilia 136 (100) 57 (100) 79 (100)
Biopsy evidence 56 (41) 22 (39) 34 (43)
Neuropathy§ 56 (41) 23 (40) 33 (42)
Nonfixed pulmonary
infiltrates
98 (72) 43 (75) 55 (70)
Sinonasal abnormality 128 (94) 55 (96) 73 (92)
Cardiomyopathyk 20 (15) 9 (16) 11 (14)
Glomerulonephritis 1 (<1) 1 (2) 0
Alveolar hemorrhage 4 (3) 1 (2) 3 (4)
Palpable purpura 17 (13) 4 (7) 13 (16)
ANCA positive 26 (19) 12 (21) 14 (18)
Relapsing disease, no. (%) 100 (74) 45 (79) 55 (70)
Refractory disease, no. (%) 74 (54) 28 (49) 46 (58)
Duration since diagnosis of
EGPA (y), mean (SD)
5.5 (4.6) 6.1 (5.0) 5.2 (4.3)
Immunosuppressive therapy
since diagnosis, no. (%)
105 (77) 45 (79) 60 (76)
Baseline OGC dose (mg/d),
no. (%)
<_7.5 18 (13) 5 (9) 13 (16)
>7.5 to <_12 55 (40) 16 (28) 39 (49)
>12 to <_20 42 (31) 21 (37) 21 (27)
>20 21 (15) 15 (26) 6 (8)
ANCA, Antineutrophil cytoplasmic antibody.Post hoc assessments and end points
Clinical benefit was a composite end point that was met if patients met at
least 1 of the following 3 component end points, which were all predefined in
the original study: (1) remission at any time during the study period (weeks 1–
52), (2) a 50% or greater reduction in OGC dose during weeks 48 to 52, or (3)
no relapses of EGPA during the study period (weeks 1–52). As in the original
study, remission was defined by using 2 separate criteria: first, a BVAS of
0 plus an OGC dose of 4 mg/d or less (remission 1), and second, an alternative
definition based on the European League Against Rheumatism (EULAR)
recommendations for clinical studies in systemic vasculitis (BVAS of 0 plus an
OGC dose <_7.5 mg/d [remission 2]).19 Therefore clinical benefit was defined
as either clinical benefit 1 when encompassing the criteria for remission 1 or
clinical benefit 2 when encompassing the criteria for remission 2. A relapse of
EGPA was defined as active vasculitis (BVAS >0), active asthma symptoms
with a corresponding worsening score on the Asthma Control
Questionnaire-6, or worsening sinonasal symptoms requiring an increase in
OGC dose to greater than 4 mg/d, an initiation or increase of immunosuppres-
sive therapy, or hospitalization.
Descriptive statistics were used to summarize the proportion (numbers and
percentages of total) of patients to meet each definition of clinical benefit.
Analyses were performed by using the as-treated population. Statistical
analyses of treatment response for mepolizumab versus placebo were
performed by using a 2-sided Fisher exact test.
*Positive ANCA status for myeloperoxidase or proteinase 3 was assessed at screening
by means of immunoassay performed at the Covance Laboratories (Princeton, NJ) and
Q2 Solutions (Morrisville, NC).
The BVAS was assessed on a scale of 0 to 63, with higher scores indicating greater
disease activity.
Biopsy evidence was defined as a biopsy specimen showing histopathologic evidence
of eosinophilic vasculitis, perivascular eosinophilic infiltration, or eosinophil-rich
granulomatous inflammation.
§Neuropathy was defined as a mononeuropathy or polyneuropathy (motor deficit or
nerve-conduction abnormality).
kThe presence of cardiomyopathy was established by means of echocardiography or
magnetic resonance imaging.Subgroups of clinical interest
End points were also assessed in specific subgroups of clinical interest,
including baseline blood eosinophil counts (BECs) of less than 150 cells/mL
and baseline OGC doses of greater than 20mg/d. Response to mepolizumab in
terms of accrued duration of remission has been reported to be lower in these
patient populations than in the general EGPA population.5,20 The subgroup of
patients weighing more than 85 kg was also investigated because weight is the
only characteristic that has been associatedwith pharmacokinetic exposure for
this biologic.21RESULTS
Patient population
Of the 151 patients enrolled in the phase III study, 136
underwent randomization; 68 were randomly assigned to receive
mepolizumab, and 68were randomly assigned to receive placebo.
All patients were included in the current analysis. Because one
patient randomized to placebo receivedmepolizumab and another
patient randomized to mepolizumab received placebo, analyses
were carried out with as-treated treatment group allocations rather
than randomized treatment assignments. Demographic andbaseline clinical characteristics of the patients are summarized
in Table I.Efficacy within the as-treated population
Composite end point. By using the composite end point,
the proportion of patients experiencing any clinical benefit after
treatment with mepolizumab ranged from 78% to 87% depending
on the remission criteria used (Fig 1) compared with 32% to 53%
of patients receiving placebo.
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FIG 1. Summary of clinical benefit after treatment with placebo or mepolizumab (as-treated population).
Clinical benefit was defined as follows: clinical benefit 1 (remission 1 at any time during the study treatment
period or >_50% reduction in average OGC dose during weeks 48–52 or no EGPA relapses during the study
period) or clinical benefit 2 (remission 2 at any time during the study treatment period or >_50% reduction in
average OGC dose during weeks 48–52 or no EGPA relapses during the study period). Remission 1 criteria:
BVAS of 0 plus OGC dose of 4mg/d or less; remission 2 criteria: BVAS of 0 and OGC dose of 7.5mg/d or less.
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of 4mg/d or less (remission 1) at any time during the study period,
78% (53/68) of patients in themepolizumab group compared with
32% (22/68) in the placebo group experienced clinical benefit 1
(P < .001; Fig 1, A).
When the definition of clinical benefit included the EULAR
remission criteria of a BVAS of 0 plus anOGC dose of 7.5mg/d or
less (remission 2), the proportion of patients experiencing clinical
benefit 2 was 87% (59/68) in the mepolizumab group versus 53%
(36/68) in the placebo group (P <.001; Fig 1, B). This increase in
the proportion of patients experiencing clinical benefit was driven
by an increase to 79% (54/68) of patients in the mepolizumab
group and 46% (31/68) of patients in the placebo group achieving
EULAR-defined remission during the study period.
Individual components of the composite end point.
When assessing the individual components from the composite
end point, 53% (36/68) of patients receiving mepolizumab
achieved remission 1 (BVAS 5 0 plus OGC dose <_4 mg/d) at
any time during the study period compared with 19% (13/68) of
patients receiving placebo (P < .001). Additionally, 57% (39/68)
of patients receiving mepolizumab were able to reduce their OGC
dose by 50% or greater compared with 21% (14/68) of patients
receiving placebo (P < .001), and 44% (30/68) of patients
receiving mepolizumab were relapse free versus 18% (12/68) of
patients receiving placebo (P 5 .001; Fig 1, A).
Combinations of components included in the com-
posite end point. In addition to assessing the proportion of
patients who met the composite end point, a more detailed
analysis was conducted of the proportion of patients who met
each combination of component end points (Fig 2). Overall, 29%
(20/68) of patients in the mepolizumab groupmet all 3 definitionsof clinical benefit 1 (remission 1 at any time [BVAS5 0 plus OGC
dose <_4 mg/d] plus >_50% OGC dose reduction and no EGPA re-
lapses) compared with only 7% (5/68) of patients in the
placebo group (Fig 2). Notably, 25% (17/68) of patients receiving
mepolizumab versus 13% (9/68) of patients receiving placebo
achieved a 50% or greater reduction in OGC dose, no EGPA
relapses, or both, despite not achieving remission 1 (BVAS 5 0
plus OGC dose <_4 mg/d). Fifteen (22%) patients receiving
mepolizumab were unable to meet any of the 3 components of
clinical benefit compared with 46 (68%) of the patients receiving
placebo (Fig 2).Efficacy within selected clinical subgroups
Baseline BEC. For patients with baseline BECs of less than
150 cells/mL, there was evidence of clinical benefit from treatment
with mepolizumab. When clinical benefit included remission 1
(BVAS5 0 plusOGC<_4mg/d), patients in this subgroup receiving
mepolizumabexperienced significantly greater clinical benefit than
patients receiving placebo; overall, 72% (21/29) of patients
receiving mepolizumab experienced clinical benefit 1 compared
with 43% (12/28) of patients receiving placebo (P5.033; Fig 3,A).
When clinical benefit included remission 2 (BVAS5 0 plus OGC
dose<_7.5mg/d), the increase in clinical benefit observedamongpa-
tients receivingmepolizumabversus patients receiving placebowas
not significant at the 5% level but was directionally in favor of
mepolizumab; 79% (23/29) of patients receiving mepolizumab
experienced clinical benefit 2 compared with 54% (15/28) of pa-
tients receiving placebo (P5 .052; Fig 3, A).
OGC dose. For patients with baseline OGC doses of greater
than 20 mg/d, treatment with mepolizumab did not lead to a
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reduction2
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benefit criterion
15 (22%)
A B
FIG 2. Summary of the proportion of patients receiving placebo ([A] n 5 68) and mepolizumab ([B] n 5 68)
to meet each definition of clinical benefit. Remission 1 criteria: BVAS of 0 and OGC dose of 4 mg/d or less
during the study treatment period; remission 2 criteria: 50% or greater reduction in average OGC dose dur-
ing weeks 48 to 52; remission 3 criteria: no EGPA relapses during the study treatment period.
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with placebo; however, results were directionally in favor of
mepolizumab compared with placebo. When clinical benefit
included remission 1 (BVAS 5 0 plus OGC dose <_4 mg/d), 60%
(6/10) of patients in the mepolizumab treatment group experi-
enced clinical benefit 1 compared with 36% (4/11) of patients in
the placebo group (P 5 .359; Fig 3, B). When clinical benefit
included remission 2, 70% (7/10) of patients in the mepolizumab
treatment group compared with 36% (4/11) of patients in the pla-
cebo group experienced clinical benefit 2 (P 5 .198; Fig 3, B).
Baseline weight. Within the subgroup of patients with
baseline weight of greater than 85 kg, mepolizumab provided
greater clinical benefit than placebo for both definitions of
clinical benefit. When clinical benefit included the remission
definition of a BVAS of 0 plus an OGC dose of 4 mg/d or less
(remission 1), 68% (13/19) of patients receiving mepolizumab
experienced clinical benefit 1 compared with 23% (6/26) of
patients receiving placebo (P 5 .005; Fig 3, C). When clinical
benefit included the EULAR remission criteria (remission 2),
89% (17/19) of patients receiving mepolizumab experienced
clinical benefit 2 compared with 46% (12/26) of patients
receiving placebo (P 5 .004; Fig 3, C).DISCUSSION
These post hoc analyses provide a broader overview of the ef-
ficacy of mepolizumab in patients with relapsing or refractory
EGPA by using data from the recent phase III trial.5 Results
from this analysis show that more patients treated with
mepolizumab versus patients treated with placebo experienced
clinical benefit according to the composite end point used. This
end point incorporated the predefined primary end point from
the phase III trial (remission [BVAS 5 0 plus OGC dose
<_4 mg/d] at any time during weeks 1–52) or remission as defined
by the EULAR remission criteria (BVAS 5 0 plus OGC dose
<_7.5 mg/d), as well as 2 additional predefined and clinically rele-
vant end points from the trial (>_50% reduction in OGC dose dur-
ing weeks 48–52 and no relapses of EGPA during weeks 1–52),
with the aim of further assessing clinical responses that are mean-
ingful for health care providers and patients with EGPA.The primary end point in the phase III clinical trial, total
accrued time of remission,5 was developed with the US Food and
Drug Administration for regulatory purposes and was designed to
capture a meaningful difference because of treatment in a condi-
tion with frequent relapses. What is notable here is that patients
also experienced additional forms of clinical benefit that had a
substantial influence on their experience of disease, such as a
lack of EGPA relapse or a reduction in OGC dose. By using a
broader but still clinically relevant definition of clinical benefit,
these assessments provide additional insight into patient re-
sponses to treatment with mepolizumab.
There are many reasons why a patient might have been able to
meet one definition of clinical benefit but not another, depending
on the specific nature of their disease. In particular, an OGC dose
of 4 mg/d or less (required to meet protocol-defined remission)
would have been difficult to achieve for patients with a high
burden of disease who entered the study on a dose of greater than
20mg/d. However, results from the current assessments show that
patients who did not achieve remission might have experienced
other forms of clinical benefit, such as having a 50% or greater
decrease in daily OGC dose compared with baseline and being
relapse free (exacerbation free) throughout the study period.
There was a relatively high response rate in the placebo group
(up to 53%) when using the definition of clinical benefit that used
either remission criterion. This might indicate that many patients
were receiving greater OGC doses than necessary at baseline and
highlights the importance of optimizing patients’ OGC doses in
clinical practice.
Overall, among patients with baseline BECs of less than
150 cells/mL, a greater proportion of patients experienced clinical
benefit with mepolizumab versus placebo. In this subgroup higher
proportions of patients receivingmepolizumab achieved a 50% or
greater reduction in OGC dose during weeks 48 to 52 and were
relapse free during the treatment period compared with patients
receiving placebo. For clinical benefit 1 (remission criteria 1:
BVAS5 0 andOGC<_4mg/d) but not clinical benefit 2 (remission
criteria 2: BVAS5 0 and OGC <_7.5 mg/d), a significantly greater
proportion of patients receiving mepolizumab experienced any
clinical benefit compared with patients receiving placebo. Of
note, patients with BECs of less than 150 cells/mL more
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FIG 3. Summary of clinical benefit in the baseline BEC of less than 150 cells/mL ([A] n 5 57), baseline OGC
dose of greater than 20 mg/d ([B] n 5 21), and weight of greater than 85 kg ([C] n 5 45) subgroups. Clinical
benefit was defined as follows: clinical benefit 1 (remission 1 at any time during the study treatment period
or >_50% reduction in average OGC dose during weeks 48–52 or no EGPA relapses during the study period)
or clinical benefit 2 (remission 2 at any time during the study treatment period or >_50% reduction in average
OGC dose during weeks 48–52 or no EGPA relapses during the study period). Remission 1 criteria: BVAS of
0 plus OGC dose of 4 mg/d or less; remission 2 criteria: BVAS of 0 plus OGC dose of 7.5 mg/d or less.
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them to achieve protocol-defined remission while following the
recommended tapering schedule. This might partially explain
why mepolizumab has previously been associated with a lower
accrued duration of remission in patients with a BEC of less than
150 cells/mL compared with patients with a BEC of 150 cells/mL
or greater.5,20 In the subgroup of patients with a baseline OGC
dose of greater than 20 mg/d, results for the individual compo-
nents of the composite end point were not consistent; however,
the proportions of patients to experience any clinical benefit 1
and clinical benefit 2 were greater among patients treated with
mepolizumab versus those treated with placebo (not significant).
Additionally, in the subgroup of patients with weights of greater
than 85 kg, significantly greater proportions of patients treated
with mepolizumab versus patients treated with placebo experi-
enced clinical benefit 1 and clinical benefit 2.
Other studies that have investigated the use of mepolizumab for
the treatment of EGPA have also reported on the ability of
mepolizumab to induce remission, prevent relapses, and allow a
reduction in glucocorticoid dose.15,17 In a pilot study of
mepolizumab in patients with EGPA,15 the glucocorticoid-
sparing effect of mepolizumab was investigated as a primary
end point. A 64% reduction in mean OGC dose, from
12.9 mg/d at baseline to 4.6 mg/d after 12 weeks of therapy
(P < .001), was observed. Additionally, in a phase II trial of
mepolizumab,17 80% (8/10) of patients achieved remission
(EULAR remission criteria) at week 32, 100% (10/10) of patients
experienced no EGPA relapses during treatment, and the median
daily glucocorticoid dose was reduced from 19 mg at baseline to
4 mg at week 32 (P5 .006). The glucocorticoid-sparing effect of
mepolizumab is also supported by the results of the recent phase
III trial.5 During weeks 48 to 52, 44% (30/68) of patients
receiving mepolizumab versus 7% (5/68) of patients receiving
placebo were able to taper their OGC dose to 4 mg/d or less,
and 18% (12/68) versus 3% (2/68), respectively, were able to dis-
continue OGC completely.5 These results support the concept that
clinical response to mepolizumab in patients with EGPA extends
beyond remission and encompasses other benefits, including a
decrease in daily OGC dose, with the potential for a reduction
in dose-related side effects. Further work is currently underway
to identify biomarkers that can predict disease activity or relapse
in patients with EGPA and might help to identify those who could
be more responsive to treatment.
This analysis had several limitations. First, the number of
patients in the baseline OGC dose of greater than 20 mg/d sub-
group was low (n 5 21), and therefore caution should be taken
when interpreting the results for this particular subgroup. Second,
because of the ability of OGCs to suppress BECs, patients with
greater baseline OGC doses would have been more likely to have
lower baseline BECs. As such, there was considerable correlation
between the baseline OGC dose of greater than 20 mg/d and
baseline eosinophil count of less than 150 cells/mL subgroups.
This assessment of the recent mepolizumab phase III clinical
trial5 investigated a broader definition of clinical benefit to help
classify and assess treatment response in patients with relapsing
or refractory EGPA. The results presented here show that treat-
ment with mepolizumab provides clinical benefit by allowing a
reduction in OGC dose in most patients. Additionally, patients
experienced clinical benefit through a decrease in the number of
EGPA relapses, which, even in the absence of remission, means
that patients are subject to fewer increases in glucocorticoiddose to manage their disease. Overall, the analyses performed
in this study provide insights that are complementary to those
of the phase III primary end point assessment and identify clinical
responses to mepolizumab that are meaningful to both patients
and providers.
Editorial support (in the form of writing assistance, including development
of the initial draft, assembling tables and figures, collating authors comments,
grammatical editing, and referencing) was provided by Natasha Dean, MSc,
and Elizabeth Hutchinson, PhD, CMPP, at Fishawack Indicia and was funded
by GlaxoSmithKline.
Clinical implications: Mepolizumab provides clinical benefit in
terms of remission, glucocorticoid dose reduction, and reduced
relapses in patients with relapsing or refractory EGPA.REFERENCES
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